11月12日晚间，以岭药业（002603）发布公告称，公司全资孙公司衡水万洋收到国家药品监督管理局下 发的《化学原料药上市申请批准通知书》，由衡水万洋提交的"盐酸美金刚"化学原料药上市申请已获批 准。 无独有偶，就在十几天前，以岭药业还有另一款化学原料药上市申请获批。据公告，由衡水万洋提交 的"阿那曲唑"化学原料药上市申请已获国家药品监督管理局批准。 据介绍，盐酸美金刚(MemantineHydrochloride)是一种电压依赖性、中等程度亲和力的非竞争性NMDA 受体拮抗剂，它可以阻断谷氨酸浓度病理性升高导致的神经元损伤，治疗中重度至重度阿尔茨海默型痴 呆。 阿那曲唑(Anastrozole)是一种广泛应用于治疗雌激素相关肿瘤的药物。以岭药业表示，公司全资孙公司 北京以岭生物持有阿那曲唑片制剂批文，该产品为集采产品，预计今年可实现原料药制剂一体化生产， 有力提高原料药和制剂的市场竞争力。另外，公司将以本次国内获批为契机，根据出海规划，加速推进 阿那曲唑原料药的国际注册和海外销售，进一步打开欧美等海外市场。 2024《中国阿尔茨海默病报告》显示，全国现存痴呆患者约1690万人，患病率约1.19‰，随人口老龄 ...

11月12日晚间，以岭药业（002603）发布公告称，公司全资孙公司衡水万洋收到国家药品监督管理局下 发的《化学原料药上市申请批准通知书》，由衡水万洋提交的"盐酸美金刚"化学原料药上市申请已获批 准。 据介绍，盐酸美金刚(MemantineHydrochloride)是一种电压依赖性、中等程度亲和力的非竞争性NMDA 受体拮抗剂，它可以阻断谷氨酸浓度病理性升高导致的神经元损伤，治疗中重度至重度阿尔茨海默型痴 呆。 据2024《中国阿尔茨海默病报告》显示，全国现存痴呆患者约1690万人，患病率约1.19‰，随人口老龄 化呈现快速上升的趋势。米内网数据显示，中国抗痴呆市场规模15.6亿元，其中美金刚是一线治疗药 物，市场份额22%。2025年，中国盐酸美金刚市场容量预计达到3.4亿元，同比增长11%；销售量1.6亿 片，同比增长19%，销售呈现持续增长的趋势。 公告称，盐酸美金刚被我国和FDA批准用于中重度AD患者，是国内外指南推荐的一线药物。预计随着 中国人口老龄化的进程加快，盐酸美金刚的市场需求将稳步上升。目前国内已有多家盐酸美金刚原料供 应商，衡水万洋将以本次国内获批为契机，提升市场份额。 无独有偶，就在十 ...

Core Viewpoint - Yiling Pharmaceutical (002603) announced the approval of its subsidiary Hengtai Wanyang's application for the chemical raw material drug Anastrozole by the National Medical Products Administration [1] Group 1 - Yiling Pharmaceutical's wholly-owned subsidiary, Hengtai Wanyang Pharmaceutical Co., Ltd., received the approval notice for the listing application of Anastrozole [1]

Core Viewpoint - Yiling Pharmaceutical (002603) announced that its wholly-owned subsidiary, Wanyang Hengshui Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of Anastrozole, a drug used primarily for treating estrogen-related tumors, particularly in postmenopausal women with hormone receptor-positive breast cancer [1]. Company Summary - Yiling Pharmaceutical's subsidiary, Wanyang Hengshui, has successfully obtained a marketing approval for Anastrozole [1]. - Anastrozole is widely used in the treatment of estrogen-related tumors, especially in postmenopausal women with HR+ breast cancer [1].

Core Viewpoint - Yiling Pharmaceutical (002603.SZ) announced that its wholly-owned subsidiary, Wanyang Hengshui Pharmaceutical Co., Ltd., has received the approval notice for the listing application of Anastrozole chemical raw material from the National Medical Products Administration [1] Group 1: Product Approval - The listing application for Anastrozole, a drug widely used for treating estrogen-related tumors, particularly in postmenopausal hormone receptor-positive (HR+) female breast cancer patients, has been approved [1] - Yiling Pharmaceutical's wholly-owned subsidiary, Beijing Yiling Biotechnology Co., Ltd., holds the formulation approval for Anastrozole tablets, which are part of a centralized procurement product [1] Group 2: Production Integration - The company expects to achieve integrated production of raw materials and formulations for Anastrozole this year [1]